BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 32899140)

  • 1. The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis.
    Tsukazaki H; Kaito T
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis.
    McGonagle D; Watad A; Sharif K; Bridgewood C
    Front Immunol; 2021; 12():614255. PubMed ID: 33815371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute anterior uveitis and other extra-articular manifestations of spondyloarthritis.
    Mitulescu TC; Popescu C; Naie A; Predeţeanu D; Popescu V; Alexandrescu C; Voinea LM
    J Med Life; 2015; 8(3):319-25. PubMed ID: 26351533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ILC3 in Axial Spondyloarthritis: the Gut Angle.
    Mauro D; Macaluso F; Fasano S; Alessandro R; Ciccia F
    Curr Rheumatol Rep; 2019 Jun; 21(7):37. PubMed ID: 31197599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whodunit? The Contribution of Interleukin (IL)-17/IL-22-Producing γδ T Cells, αβ T Cells, and Innate Lymphoid Cells to the Pathogenesis of Spondyloarthritis.
    Reinhardt A; Prinz I
    Front Immunol; 2018; 9():885. PubMed ID: 29922283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-17 in the immunopathogenesis of spondyloarthritis.
    Taams LS; Steel KJA; Srenathan U; Burns LA; Kirkham BW
    Nat Rev Rheumatol; 2018 Aug; 14(8):453-466. PubMed ID: 30006601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Trials Supporting the Role of the IL-17/IL-23 Axis in Axial Spondyloarthritis.
    Ceribelli A; Motta F; Vecellio M; Isailovic N; Ciccia F; Selmi C
    Front Immunol; 2021; 12():622770. PubMed ID: 34149686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extra-articular disease in patients with spondyloarthritis. Baseline characteristics of the spondyloarthritis cohort of the AQUILES study.
    Zarco P; González CM; Rodríguez de la Serna A; Peiró E; Mateo I; Linares L; Calvo J; Cea-Calvo L; Arteaga MJ; Vanaclocha F; Marín-Jiménez I; García-Vicuña R
    Reumatol Clin; 2015; 11(2):83-9. PubMed ID: 25441489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis.
    Yeremenko N; Paramarta JE; Baeten D
    Curr Opin Rheumatol; 2014 Jul; 26(4):361-70. PubMed ID: 24827753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-23 pathway at the enthesis: The emerging story of enthesitis in spondyloarthropathy.
    Bridgewood C; Sharif K; Sherlock J; Watad A; McGonagle D
    Immunol Rev; 2020 Mar; 294(1):27-47. PubMed ID: 31957051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy?
    Mitulescu TC; Trandafir M; Dimăncescu MG; Ciuluvică RC; Popescu V; Predețeanu D; Istrate S; Voinea LM
    Rom J Ophthalmol; 2018; 62(2):114-122. PubMed ID: 30206554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis?
    Rosine N; Miceli-Richard C
    Front Immunol; 2020; 11():553742. PubMed ID: 33488572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The IL-23/IL-17A axis in spondyloarthritis: therapeutics informing pathogenesis?
    Siebert S; McGucken A; McInnes IB
    Curr Opin Rheumatol; 2020 Jul; 32(4):349-356. PubMed ID: 32412997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of the IL-23/IL-17 Axis in Disease Initiation in Spondyloarthritis: Lessons Learned From Animal Models.
    Mandour M; Chen S; van de Sande MGH
    Front Immunol; 2021; 12():618581. PubMed ID: 34267743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis.
    Gravallese EM; Schett G
    Nat Rev Rheumatol; 2018 Nov; 14(11):631-640. PubMed ID: 30266977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nature versus nurture in the spectrum of rheumatic diseases: Classification of spondyloarthritis as autoimmune or autoinflammatory.
    Generali E; Bose T; Selmi C; Voncken JW; Damoiseaux JGMC
    Autoimmun Rev; 2018 Sep; 17(9):935-941. PubMed ID: 30005857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-23 and axial disease: do they come together?
    Mease P; van den Bosch F
    Rheumatology (Oxford); 2021 Oct; 60(Suppl 4):iv28-iv33. PubMed ID: 34668015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-23/IL-17 axis in spondyloarthritis-bench to bedside.
    Raychaudhuri SP; Raychaudhuri SK
    Clin Rheumatol; 2016 Jun; 35(6):1437-41. PubMed ID: 27075462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One year in review 2018: axial spondyloarthritis.
    Carli L; Calabresi E; Governato G; Braun J
    Clin Exp Rheumatol; 2019; 37(6):889-898. PubMed ID: 31796161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory pathways in spondyloarthritis.
    Hreggvidsdottir HS; Noordenbos T; Baeten DL
    Mol Immunol; 2014 Jan; 57(1):28-37. PubMed ID: 23969080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.